HRP20010878B1 - Ziprasidone suspension - Google Patents

Ziprasidone suspension

Info

Publication number
HRP20010878B1
HRP20010878B1 HR20010878A HRP20010878A HRP20010878B1 HR P20010878 B1 HRP20010878 B1 HR P20010878B1 HR 20010878 A HR20010878 A HR 20010878A HR P20010878 A HRP20010878 A HR P20010878A HR P20010878 B1 HRP20010878 B1 HR P20010878B1
Authority
HR
Croatia
Prior art keywords
ziprasidone
suspension
ziprasidone suspension
polysorbate
pharmaceutically acceptable
Prior art date
Application number
HR20010878A
Other languages
English (en)
Croatian (hr)
Inventor
Ray Arenson Daniel
Qi Hong
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22472103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20010878(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HRP20010878A2 publication Critical patent/HRP20010878A2/hr
Publication of HRP20010878B1 publication Critical patent/HRP20010878B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Cosmetics (AREA)
  • Dental Preparations (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
HR20010878A 1999-05-27 2001-11-26 Ziprasidone suspension HRP20010878B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13626899P 1999-05-27 1999-05-27
PCT/IB2000/000593 WO2000072847A1 (en) 1999-05-27 2000-05-08 Ziprasidone suspension

Publications (2)

Publication Number Publication Date
HRP20010878A2 HRP20010878A2 (en) 2003-06-30
HRP20010878B1 true HRP20010878B1 (en) 2007-03-31

Family

ID=22472103

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010878A HRP20010878B1 (en) 1999-05-27 2001-11-26 Ziprasidone suspension

Country Status (50)

Country Link
EP (1) EP1181018B1 (no)
JP (1) JP3942827B2 (no)
KR (1) KR100477782B1 (no)
CN (1) CN1196486C (no)
AP (1) AP1409A (no)
AR (1) AR022643A1 (no)
AT (1) ATE234097T1 (no)
AU (1) AU777413B2 (no)
BG (1) BG65367B1 (no)
BR (1) BR0010990A (no)
CA (1) CA2371550C (no)
CO (1) CO5170458A1 (no)
CR (1) CR6506A (no)
CU (1) CU23223B7 (no)
CZ (1) CZ20014230A3 (no)
DE (1) DE60001649T2 (no)
DK (1) DK1181018T3 (no)
DZ (1) DZ3049A1 (no)
EA (1) EA003907B1 (no)
EE (1) EE04704B1 (no)
ES (1) ES2191618T3 (no)
GC (1) GC0000190A (no)
GE (1) GEP20033113B (no)
GT (1) GT200000081A (no)
HK (1) HK1046366B (no)
HN (1) HN2000000071A (no)
HR (1) HRP20010878B1 (no)
HU (1) HUP0201297A3 (no)
IL (2) IL145950A0 (no)
IS (1) IS2396B (no)
MA (1) MA26741A1 (no)
MX (1) MXPA01012124A (no)
MY (1) MY127891A (no)
NO (1) NO320296B1 (no)
NZ (1) NZ514764A (no)
OA (1) OA11946A (no)
PA (1) PA8495801A1 (no)
PE (1) PE20010127A1 (no)
PL (1) PL196867B1 (no)
RS (1) RS50089B (no)
SI (1) SI1181018T1 (no)
SK (1) SK284590B6 (no)
SV (1) SV2001000085A (no)
TN (1) TNSN00112A1 (no)
TR (1) TR200103392T2 (no)
TW (1) TWI263498B (no)
UA (1) UA59491C2 (no)
UY (1) UY26166A1 (no)
WO (1) WO2000072847A1 (no)
ZA (1) ZA200109692B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CN1407884B (zh) 1999-10-29 2012-06-20 欧罗赛铁克股份有限公司 控释氢可酮制剂
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
JP4619658B2 (ja) * 2002-03-12 2011-01-26 富山化学工業株式会社 快い味の経口懸濁液および方法
JP2006505579A (ja) * 2002-10-25 2006-02-16 ファイザー・プロダクツ・インク 懸濁形態でのアリール複素環活性薬物の蓄積製剤
RU2310450C2 (ru) * 2002-10-25 2007-11-20 Пфайзер Продактс Инк. Новые депо-препараты для инъекций
EP1418492B1 (en) 2002-11-05 2017-09-20 LG Electronics, Inc. Touch screen mounting assembly for LCD monitor
CA2543805A1 (en) 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
WO2006085168A2 (en) * 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
CN101879140A (zh) * 2005-06-20 2010-11-10 依兰药物国际有限公司 包含芳基-杂环化合物的毫微粒和控制释放组合物
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
JP4336380B1 (ja) * 2008-11-06 2009-09-30 塩野義製薬株式会社 水懸濁性を向上させた細粒剤
JP6272730B2 (ja) * 2014-05-21 2018-01-31 救急薬品工業株式会社 速溶性フィルム剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
TNSN00112A1 (fr) 2005-11-10
NO20015755D0 (no) 2001-11-26
PA8495801A1 (es) 2001-12-14
NO20015755L (no) 2002-01-23
AR022643A1 (es) 2002-09-04
MXPA01012124A (es) 2002-06-04
TR200103392T2 (tr) 2002-11-21
DE60001649D1 (de) 2003-04-17
GC0000190A (en) 2006-03-29
BR0010990A (pt) 2002-03-05
IL145950A0 (en) 2002-07-25
KR100477782B1 (ko) 2005-03-21
MA26741A1 (fr) 2004-12-20
CA2371550A1 (en) 2000-12-07
CA2371550C (en) 2007-01-02
CN1352560A (zh) 2002-06-05
HRP20010878A2 (en) 2003-06-30
NZ514764A (en) 2004-04-30
AP1409A (en) 2005-06-13
CR6506A (es) 2004-03-24
GT200000081A (es) 2001-11-16
DZ3049A1 (fr) 2004-03-27
EA200101131A1 (ru) 2002-04-25
TWI263498B (en) 2006-10-11
ES2191618T3 (es) 2003-09-16
MY127891A (en) 2006-12-29
BG65367B1 (bg) 2008-04-30
DK1181018T3 (da) 2003-04-22
EA003907B1 (ru) 2003-10-30
PE20010127A1 (es) 2001-02-06
CU23223B7 (es) 2007-08-30
CZ20014230A3 (cs) 2002-08-14
OA11946A (en) 2006-04-13
HK1046366A1 (en) 2003-01-10
EP1181018B1 (en) 2003-03-12
WO2000072847A1 (en) 2000-12-07
JP2003500449A (ja) 2003-01-07
EE200100633A (et) 2003-02-17
BG106153A (bg) 2002-06-28
ATE234097T1 (de) 2003-03-15
EE04704B1 (et) 2006-10-16
DE60001649T2 (de) 2003-08-21
SI1181018T1 (en) 2003-06-30
PL352826A1 (en) 2003-09-08
NO320296B1 (no) 2005-11-21
AU777413B2 (en) 2004-10-14
RS50089B (sr) 2009-01-22
IL145950A (en) 2007-12-03
SK284590B6 (sk) 2005-07-01
YU76701A (sh) 2005-07-19
SV2001000085A (es) 2001-11-08
HK1046366B (zh) 2005-07-29
PL196867B1 (pl) 2008-02-29
AP2001002346A0 (en) 2001-12-31
HUP0201297A2 (en) 2002-08-28
HN2000000071A (es) 2001-02-02
ZA200109692B (en) 2002-11-26
UY26166A1 (es) 2000-12-29
IS6134A (is) 2001-10-30
CN1196486C (zh) 2005-04-13
KR20020048307A (ko) 2002-06-22
GEP20033113B (en) 2003-11-25
SK16782001A3 (sk) 2002-09-10
HUP0201297A3 (en) 2005-09-28
CO5170458A1 (es) 2002-06-27
UA59491C2 (uk) 2003-09-15
IS2396B (is) 2008-08-15
JP3942827B2 (ja) 2007-07-11
AU4138500A (en) 2000-12-18
EP1181018A1 (en) 2002-02-27

Similar Documents

Publication Publication Date Title
HRP20010878B1 (en) Ziprasidone suspension
RU2002109814A (ru) Новые производные аминодикарбоновых кислот, обладающие фармацевтическими свойствами
MY135119A (en) Stabilized oral suspension formulation
MA26932A1 (fr) Derives d'imidazole.
HRP20060240T3 (en) Intranasal formulation of rotigotine
DK1169392T3 (da) Vandbaserede polyamidamidsyresammensætninger
MXPA01012547A (es) Imidazoquinolinas sustituidas con sulfonamida y sulfamida.
HRP20020198B1 (en) Moxifloxacin formulation containing common salt
MA26816A1 (fr) Derives d'amino-triazolopyridine
RS49611B (sr) Ziprasidon formulacije
BR9916857A (pt) 4 heteroaril diarilaminas
HRP20010573B1 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
RS49609B (sr) Stabilizovani antihistaminski sirup
RU2001126719A (ru) Дигетерозамещенные ингибиторы металлопротеазы
ATE289478T1 (de) Ektoparasitizide wässrige suspensionsformulierungen von spinosynen
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
NO20040702L (no) Kombinerte preparater som inneholder 1,4-benzotiepin-1,1-dioksidderivater og andre aktive substanser og anvendelsen derav
DK1204659T3 (da) Serotonerge benzofuraner
TR199900730T2 (xx) S�v� alendronat form�lasyonlar�
HRP20010764B1 (en) Prucalopride oral solution
SE0001916D0 (sv) Novel formulation
HRP20020332B1 (en) Oral solution containing galanthamine and a sweetening agent
RU2000118409A (ru) Антимутагенное средство
MA25447A1 (fr) Concept d'affichage publicitaire sur le sol.
IT251674Y1 (it) "perfezionamento nei dispositivi denominati idrobar,idrotuba,idrosfera e simili".

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20080421

Year of fee payment: 9

PBON Lapse due to non-payment of renewal fee

Effective date: 20090509